Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Net Cash Flow (2022 - 2025)

BioXcel Therapeutics has reported Net Cash Flow over the past 4 years, most recently at -$8.6 million for Q4 2025.

  • Quarterly results put Net Cash Flow at -$8.6 million for Q4 2025, up 18.7% from a year ago — trailing twelve months through Dec 2025 was -$1.1 million (up 96.9% YoY), and the annual figure for FY2025 was -$1.1 million, up 96.9%.
  • Net Cash Flow for Q4 2025 was -$8.6 million at BioXcel Therapeutics, down from $18.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for BTAI hit a ceiling of $18.7 million in Q3 2025 and a floor of -$38.6 million in Q4 2022.
  • Median Net Cash Flow over the past 4 years was -$16.9 million (2024), compared with a mean of -$16.9 million.
  • Biggest five-year swings in Net Cash Flow: crashed 3202.64% in 2023 and later skyrocketed 218.01% in 2025.
  • BioXcel Therapeutics' Net Cash Flow stood at -$38.6 million in 2022, then soared by 35.89% to -$24.7 million in 2023, then surged by 57.43% to -$10.5 million in 2024, then grew by 18.7% to -$8.6 million in 2025.
  • The last three reported values for Net Cash Flow were -$8.6 million (Q4 2025), $18.7 million (Q3 2025), and -$12.4 million (Q2 2025) per Business Quant data.